Online inquiry

IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3988MR)

This product GTTS-WQ3988MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LTB&TNFSF14 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002341.2; NM_003807.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4050; 8740
UniProt ID Q06643; O43557
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3988MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9748MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ11854MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ15950MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ9829MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ575MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ14868MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ10496MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ11655MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MHAA4549A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW